Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)

被引：1
|
作者：
Harter, P. [1 ]
du Bois, A. [1 ]
Hilpert, F. [2 ]
Kerkmann, M. [3 ]
Sehouli, J. [4 ]
Mahner, S. [5 ]
de Gregorio, N. [6 ]
Hanker, L. [7 ]
Heitz, F. [1 ]
Marme, F. [8 ]
Woelber, L. [9 ,10 ]
Holtmann, L. [3 ]
Elser, G. [11 ]
Pfisterer, J. [12 ]
机构：
[1] Kliniken Essen Mitte Evang Huyssens Stiftung, Gynaecol & Gynaecol Oncol, Essen, Germany
[2] Krankenhaus Jerusalem, Onkolog Therapiezentrum, Hamburg, Germany
[3] MMF GmbH, MMF Munster, Munster, Germany
[4] Univ Klin Charite, Gynaecol, Campus Virchow Klinikum, Berlin, Germany
[5] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Obstet & Gynaecol, Munich, Germany
[6] SLK Kliniken Heilbronn GmbH, Gynaecol, Heilbronn, Germany
[7] Univ SH Lubeck, Gynecol & Obstet, Lubeck, Germany
[8] Heidelberg Univ, Univ Hosp Mannheim, Med Oncol, Mannheim, Germany
[9] AGO, Gynecol Dept, Hamburg, Germany
[10] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[11] AGO Res GmbH, AGO Study Grp, Wiesbaden, Germany
[12] Gynakol & Gynakol Onkol Kiel Prof Dr Jacobus Pfis, Gynaecol Oncol Dept, Kiel, Germany
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533P
引用
收藏
页码：S791 / S792
页数：2
相关论文
共 50 条
  • [1] Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group).
    Mahner, Sven
    Harter, Philipp
    Du Bois, Andreas
    Hilpert, Felix
    Kerkmann, Markus
    Sehouli, Jalid
    de Gregorio, Nikolaus
    Hanker, Lars Ch.
    Heitz, Florian
    Marme, Frederik
    Woelber, Linn Lena
    Holtmann, Laura
    Elser, Gabriele
    Pfisterer, Jacobus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17613 - E17613
  • [2] Real World Data on Therapy and Disease Progression of Patients with First Recurrence of Ovarian Cancer in Germany (QS Ovar of the AGO Study Group)
    Schmalfeldt, B.
    du Bois, A.
    Pfisterer, J.
    Hilpert, F.
    Kerkmann, M.
    Sehouli, J.
    Mahner, S.
    de Gregorio, N.
    Hanker, L.
    Heitz, F.
    Marme, F.
    Woelber, L.
    Holtmann, L.
    Krueger, A.
    Harter, P.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10) : E157 - E158
  • [3] REAL WORLD DATA OF TREATMENT AND OUTCOME OF PATIENTS WITH HIGH GRADE AOC (ADVANCED OVARIAN CANCER) IN GERMANY (QS OVAR)
    Harter, P.
    Du Bois, A.
    Hilpert, F.
    Kerkmann, M.
    Sehouli, J.
    Mahner, S.
    De Gregorio, N.
    Hanker, L.
    Heitz, F.
    Marme, F.
    Woelber, L.
    Holtmann, L.
    Pfisterer, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A200 - A200
  • [4] Therapy of Ovarian Cancer (OC) in Germany - Treatment characteristics and Survival Results of the QS OVAR 2012
    Harter, P.
    du Bois, A.
    Hilpert, F.
    Rochon, J.
    Lamparter, C.
    Kerkmann, M.
    Pfisterer, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 85 - 85
  • [5] SURVIVAL AND TIME TO RECURRENCE IN PATIENTS WITH ADVANCED OVARIAN CANCER IN GERMANY: DATA FROM AGO QS-OVAR 2008 PROSPECTIVE COHORT
    du Bois, A.
    Harter, P.
    Hilpert, F.
    Lamparter, C.
    Rochon, J.
    Kielhorn, A.
    Sadetsky, N.
    Hecker, D.
    Pfisterer, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [6] TREATMENT PATTERNS IN THE ADVANCED OVARIAN CANCER POPULATION: DATA FROM AGO QS-OVAR 2008 PROSPECTIVE COHORT
    du Bois, A.
    Harter, P.
    Hilpert, F.
    Lamparter, C.
    Rochon, J.
    Kielhorn, A.
    Sadetsky, N.
    Hecker, D.
    Pfisterer, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [7] Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR).
    Harter, P
    Breitbach, GP
    Tanner, B
    Sehouli, J
    Heilmann, V
    Lueck, HJ
    Kuhn, W
    Wimberger, P
    Ortmann, O
    Du Bois, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 456S - 456S
  • [8] Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO organkommission ovar and the AGO ovarian cancer study group (AGO-OVAR)
    Gropp, M.
    Harter, P.
    Canzler, U.
    Richter, B.
    Jackisch, C.
    Hasenburg, A.
    Burges, A.
    Loibl, S.
    Hahmann, M.
    du Bois, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 267 - 268
  • [9] AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group.
    Harter, P
    Schade-Brittinger, C
    Belau, AK
    Sehouli, J
    Loibl, S
    Lueck, HJ
    Jackisch, C
    Canzler, U
    Kimmig, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 469S - 469S
  • [10] Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients.
    Garofalo, David
    Aydin, Ebru
    Labrador, Monica
    Webster, Jennifer
    Brown, Greg
    Donaldson, Joseph
    Gierman, Hinco Jasper
    Varughese, Prateesh
    Malik, Ash
    Scott, Jeffrey A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345